A. Busico

发表

Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.

L. Mariani, F. Perrone, N. Zaffaroni, 2018, Urologic oncology.

Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study

A. Busico, R. Murialdo, S. Lonardi, 2021, British journal of cancer.

Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group

B. Casini, A. De Vita, A. D. Dei Tos, 2020, Frontiers in Oncology.

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

V. Adamo, F. D. De Braud, L. Rimassa, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study

G. Fontanini, E. Sensi, F. Perrone, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Metformin Enhances Cisplatin‐Induced Apoptosis and Prevents Resistance to Cisplatin in Co‐mutated KRAS/LKB1 NSCLC

U. Pastorino, F. D. De Braud, A. Scarpa, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genetic layout of melanoma lesions associates to BRAF/MEK-targeted therapy resistance and to transcriptional profiles.

G. Pruneri, M. Del Vecchio, L. De Cecco, 2022, The Journal of investigative dermatology.

Toward the molecular dissection of peritoneal pseudomyxoma.

F. D. De Braud, F. Perrone, A. Busico, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer

F. Perrone, A. Busico, A. Sartore-Bianchi, 2021, Clinical Cancer Research.

Identification of potentially druggable molecular alterations in skin adnexal malignancies

G. Pruneri, F. Perrone, L. Licitra, 2019, The Journal of dermatology.

Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups

G. Sozzi, F. Perrone, E. Biganzoli, 2020, Cancers.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

G. Pruneri, F. Perrone, S. Corso, 2017, Clinical Cancer Research.

Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin

G. Pruneri, F. Perrone, A. Belfiore, 2019, Neuroendocrinology.

Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis

G. Corrao, U. Pastorino, G. Pruneri, 2020, Cancers.

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial

V. Torri, G. Sozzi, S. Indraccolo, 2020, ESMO Open.

Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic–Phenotypic Correlations to Emerge

U. Pastorino, G. Pelosi, M. Papotti, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis

U. Pastorino, G. Pruneri, P. Maisonneuve, 2020, Neuroendocrinology.

Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.

U. Pastorino, G. Pelosi, F. Perrone, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift

U. Pastorino, G. Pelosi, G. Rossi, 2017, Virchows Archiv.

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples

G. Pruneri, A. Vingiani, F. Perrone, 2022, Exploration of targeted anti-tumor therapy.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

G. Pruneri, F. Perrone, D. Rossini, 2019, Scientific Reports.

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

M. Fassan, M. Benelli, A. Sadanandam, 2019, ESMO Open.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

R. Danesi, D. Rossini, A. Busico, 2019, JAMA oncology.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

A. Bardelli, F. D. De Braud, F. Di Nicolantonio, 2016, Cancer discovery.

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.

L. Mariani, P. Ascierto, R. Miceli, 2018, European journal of cancer.

LKB1 down-modulation by miR-17 identifies NSCLC patients with worse prognosis eligible for energy-stress based treatments.

U. Pastorino, M. Boeri, G. Sozzi, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

A. Bardelli, F. Perrone, A. Gloghini, 2016, Clinical Cancer Research.

Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules

U. Pastorino, G. Pelosi, F. Perrone, 2016, Virchows Archiv.

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial

L. Mariani, F. Perrone, N. Zaffaroni, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

L. Mariani, F. Perrone, A. Gloghini, 2016, Journal of Translational Medicine.

Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).

L. Mariani, P. Ascierto, R. Miceli, 2017 .

Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group

B. Casini, A. De Vita, A. D. Dei Tos, 2020, Frontiers in Oncology.

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

L. Antonuzzo, F. Perrone, S. Murgioni, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

M. Gariboldi, F. Perrone, A. Busico, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma

U. Pastorino, G. Pelosi, G. Rossi, 2017, The journal of pathology. Clinical research.

First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open‐label, single‐arm, single‐centre, phase 2 study

L. Mariani, F. Perrone, A. Gloghini, 2018, BJU international.

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model

S. Manoukian, G. Pruneri, A. Vingiani, 2022, Frontiers in Oncology.

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

G. Pelosi, G. Rossi, A. Ardizzoni, 2015, Lung cancer.

Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.

G. Tonini, R. Danesi, D. Rossini, 2018 .

Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis

A. Vanoli, U. Pastorino, M. Papotti, 2022, Neuroendocrinology.

Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma

S. Manoukian, G. Pruneri, A. Vingiani, 2023, Scientific reports.

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma

M. Borrello, G. Pruneri, A. Vingiani, 2020, Cancers.

AKT1 and BRAF mutations in pediatric aggressive fibromatosis

S. Pilotti, A. Ferrari, A. Gronchi, 2016, Cancer medicine.

Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma

S. Pilotti, F. Perrone, A. Belfiore, 2019, International journal of molecular sciences.

SMO mutations confer poor prognosis in malignant pleural mesothelioma

U. Pastorino, G. Gatta, M. Tiseo, 2020, Translational lung cancer research.

A. Busico, R. Murialdo, S. Lonardi, 2021, British Journal of Cancer.

Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections

U. Pastorino, G. Pelosi, F. Perrone, 2016, Virchows Archiv.

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy

F. D. De Braud, G. Pruneri, A. Vingiani, 2019, Cancers.

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.

G. Apolone, S. Manoukian, G. Pruneri, 2023, JCO precision oncology.

Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.

G. Pruneri, A. Vingiani, F. Perrone, 2023, Cancer biomarkers : section A of Disease markers.

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.

G. Tonini, R. Danesi, G. Cardellino, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

G. Pruneri, F. Perrone, D. Rossini, 2019, Scientific Reports.

Can we define breast cancer HER2 status by liquid biopsy?

A. Vingiani, S. Di Cosimo, C. De Marco, 2023, International review of cell and molecular biology.

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

A. Busico, F. Braud, F. Pietrantonio, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors

B. Paolini, A. Busico, A. Greco, 2023, Frontiers in endocrinology.